An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece

PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC). Afatinib, a second-generation irreversible EGFR-TKI, has been extensively used in Greece in this setting;...

Descripción completa

Detalles Bibliográficos
Autores principales: Mountzios, Giannis, Lampaki, Sofia, Koliou, Georgia-Angeliki, Vozikis, Athanassios, Kontogiorgos, Ioannis, Papantoniou, Panagiotis, Koufaki, Margarita-Ioanna, Res, Eleni, Boutis, Anastasios, Christopoulou, Athina, Pastelli, Nicoleta, Grivas, Anastasios, Aravantinos, Gerasimos, Lalla, Efthalia, Oikonomopoulos, Georgios, Koumarianou, Anna, Spyratos, Dionisios, Bafaloukos, Dimitrios, Rigakos, Georgios, Papakotoulas, Pavlos, Fountzilas, George, Linardou, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415762/
https://www.ncbi.nlm.nih.gov/pubmed/34512058
http://dx.doi.org/10.2147/LCTT.S318007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415762/
https://www.ncbi.nlm.nih.gov/pubmed/34512058
http://dx.doi.org/10.2147/LCTT.S318007

Ejemplares similares